TLSI
TriSalus Life Sciences, Inc. · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website risaluslifesci.com
- Employees(FY) 106
- ISIN US89680M1018
Performance
+0.51%
1W
+2.39%
1M
+8.72%
3M
+149.37%
6M
+16.57%
YTD
-4.55%
1Y
Profile
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Technical Analysis of TLSI 2024-05-10
Overview:
In analyzing the technical indicators for TLSI over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions to guide your inv...
Recent News & Updates
- 2024-05-15 00:53
- 2024-05-14 20:00
- 2024-05-06 19:00
- 2024-05-06 04:58
- 2024-04-30 04:35
- 2024-04-01 00:53
- 2024-03-31 21:33
- 2024-03-31 20:00
- 2024-03-25 20:00
- 2024-03-20 20:00
- 2024-03-11 05:15
- 2024-03-06 18:00
- 2024-02-28 18:00
- 2023-12-13 18:00
- 2023-11-13 23:27
- 2023-11-13 19:00
- 2023-11-07 03:05
- 2023-11-04 02:25
- 2023-11-03 00:00
- 2023-10-24 21:05
- 2023-09-05 19:00
- 2023-08-10 04:05
- 2023-08-02 05:00
- 2023-06-11 19:00
- 2023-04-19 19:00
- 2023-02-20 18:00
- 2022-12-07 08:26
- 2022-11-14 03:24
- 2022-03-14 02:32
- 2022-03-09 19:11
Page 1 of 2
previousnext